Research graph
References from Trends and variability in the use of glucocorticoids in patients with systemic lupus erythematosus included in the RELESSER-PROS registry. Local targets link to admitted publications; unresolved targets remain external evidence.
Steroids in lupus: enemies or allies
10.3390/jcm12113639 · 2023 · External reference
Damage in a large systemic lupus erythematosus cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER) with emphasis on the cardiovascular system: a longitudinal analysis
10.1136/lupus-2023-001064 · 2024 · External reference
Damage in SLE and its association with corticosteroids
10.1002/1529-0131(200008)43:8<1801::aid-anr16>3.0.co;2-o · 2000 · External reference
Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus
10.1016/j.semarthrit.2017.01.010 · 2017 · External reference
Risk of serious infections in patients with SLE receiving immunosuppressive agents: meta-analysis
2016 · External reference
Assessing the steroid-sparing effect of biological agents in randomized controlled trials for lupus: a scoping review
10.1007/s12026-024-09463-y · 2024 · External reference
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
10.1136/annrheumdis-2019-215089 · 2019 · External reference
2023 Update of the EULAR recommendations for the management of systemic lupus erythematosus
2023 · External reference
2025 American College of Rheumatology (ACR) Guideline for the treatment of systemic lupus erythematosus
2025 · External reference
Oral glucocorticoid patterns use in moderate to severe active SLE: insights from the Spanish SPOCS data
10.1136/lupus-2025-001597 · 2025 · External reference
Glucocorticoid use in SLE: patterns and outcomes in the SLICC cohort
2020 · External reference
The burden of glucocorticoids: patterns of use, adverse health conditions, and health care use in two cohorts with systemic lupus erythematosus
10.1002/acr2.11733 · 2024 · External reference
Practice pattern variation in oral glucocorticoid therapy after the induction of response in proliferative lupus nephritis
10.1177/0961203309356292 · 2010 · External reference
Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey
10.1136/lupus-2016-000173 · 2017 · External reference
Contributions of the lupus register of the Spanish Society of Rheumatology (RELESSER) to the knowledge of systemic lupus erythematosus in Spain
10.1016/j.reuma.2020.01.006 · 2021 · External reference
National registry of patients with systemic lupus erythematosus of the Spanish Society of Rheumatology: objectives and methodology
10.1016/j.reuma.2013.04.013 · 2014 · External reference
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)
10.1136/annrheumdis-2016-209519 · 2017 · External reference
Unfavorable outcomes associated with glucocorticoid use in current standard-of-care management of systemic lupus erythematosus in Canada
10.1002/acr2.11680 · 2024 · External reference
Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study
10.1136/ard-2023-225369 · 2024 · External reference
Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS)
10.1136/lupus-2024-001336 · 2025 · External reference
No effect of low-dose glucocorticoid maintenance therapy on damage in SLE patients in prolonged remission: a propensity score analysis of the longitudinal Lupus-Cruces-Bordeaux inception cohort
10.3390/jcm13206049 · 2024 · External reference
Low-dose glucocorticoids should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual
10.1093/rheumatology/keab149 · 2021 · External reference
P114. Just a little or not at all? Differences in organ damage progression according to glucocorticoids dosages in the treatment of systemic lupus erythematosus patients. data from RELESSER-PROS Spanish multicenter prospective cohort
2025 · External reference
Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort
10.1093/rheumatology/kex444 · 2018 · External reference
